ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 119

Triage in Chronic Rheumatic Diseases: Quantitative Physician Estimates for Inflammation (Reversible), Damage (Irreversible), and Distress in Patients with Rheumatoid Arthritis, Osteoarthritis, and Fibromyalgia Seen in Usual Care

Isabel Castrejón1, Kathryn A. Gibson2, Ruchi Jain1, Annie Huang1, Joel A. Block3 and Theodore Pincus1, 1Rheumatology, Rush University Medical Center, Chicago, IL, 2Liverpool Hospital, Liverpool, Australia, 3Rush University Medical Center, Chicago, IL

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: fibromyalgia, Inflammation, joint damage, osteoarthritis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Health Services Research Poster I: Diagnosis, Management and Treatment Strategies

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: A physician estimate of a patient’s global status (DOCGL) often is most often the most efficient of all 7 rheumatoid arthritis (RA) core data set measures to distinguish active from control treatments in clinical trials(1). DOCGL is designated to assess inflammatory activity. However, DOCGL may be influenced by damage, as seen in comorbid osteoarthritis (OA), and distress, as seen in fibromyalgia and chronic pain syndromes. Indeed, it may be suggested that the expertise of a rheumatologist is directed to a form of “triage” in chronic diseases, to recognize the extent to which a patient’s signs and symptoms may be explained by inflammation, damage, and/or distress. Therefore, 3 new physician 0-10 visual analog scales (VAS) developed to estimate subsets of DOCGL. We analyzed physician scales for overall global status, inflammation, damage and distress in patients with RA, osteoarthritis (OA), and fibromyalgia (FM).

Methods: Patients seen in routine care at one academic clinical setting are assigned 4 0-10 VAS estimates for overall DOCGL, inflammation or reversible problems, damage (to any organ) or irreversible problems, and/or distress, as seen in fibromyalgia, depression, chronic pain syndrome, etc. A cross-sectional analysis was performed of a random visit between September and December 2014 of consecutive patients with 3 primary diagnoses: RA (n=108), OA (n=131), and FM (n=51). The medians and interquartile ranges (IQR) of non-normally distributed data and Spearman correlations were computed to estimate associations of the overall DOCGL with subscales and PATGL in the 3 diagnosis groups.

Results: Median DOCGL ranged from 3 to 5, highest for patients with FM (5.0), followed by OA (4), and RA (3.5). The highest median score for inflammation was for patients with RA (1.5), for damage in patients with OA (4.2) and for distress in patients with FM (5.2) (Table). The highest correlation with DOCGL was seen for the inflammation scale in RA, damage in OA, and distress in FM. DOCGL was correlated significantly with PATGL in RA and OA, but not in FM.

Conclusion: Physician estimates for inflammation, damage, and distress differ according to different rheumatic diagnoses. These 3 subscales supplement the overall physician global estimate as a quantitative summary of the history and physical examination, to estimate levels of inflammation, damage, and distress in an individual patient, analogous to triage function in acute injury, to support clinical decisions in patients with chronic rheumatic diseases in usual care.

Reference: 1)Pincus T, et al. Clin Exp Rheumatol. 2014;32 Suppl 85(5):47-54.

Table: Median (IQR) for the four physician estimates and Spearman correlations between DOCGL and the three physician subscales in addition to PATGL in the three diagnostic categories

 

RA

N=108

OA

N=131

FM

N=51

Median (IQR) for four physician global estimates

Overall DOCGL (0-10 scale)

3.5 (2-5)

4 (3.5-5)

5 (4-6)

Inflammation (0-10)

1.5 (0.5-3)

0 (0-1)

0 (0-1)

Damage (0-10)

3 (1-4)

4.2 (3-5)

1 (0-4)

Distress (0-10)

0 (0-0.7)

0 (0-3)

5.2 (4.5-7)

Spearman correlations with overall physician global estimate

Inflammation

0.72**

0.02

-0.08

Damage

0.51**

0.64**

0.13

Distress

0.31*

0.38**

0.70**

PATGL (0-10 scale)

0.61**

0.60**

0.28*

*p<0.01; **p<0.001


Disclosure: I. Castrejón, None; K. A. Gibson, None; R. Jain, None; A. Huang, None; J. A. Block, None; T. Pincus, None.

To cite this abstract in AMA style:

Castrejón I, Gibson KA, Jain R, Huang A, Block JA, Pincus T. Triage in Chronic Rheumatic Diseases: Quantitative Physician Estimates for Inflammation (Reversible), Damage (Irreversible), and Distress in Patients with Rheumatoid Arthritis, Osteoarthritis, and Fibromyalgia Seen in Usual Care [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/triage-in-chronic-rheumatic-diseases-quantitative-physician-estimates-for-inflammation-reversible-damage-irreversible-and-distress-in-patients-with-rheumatoid-arthritis-osteoarthritis-and-fib/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/triage-in-chronic-rheumatic-diseases-quantitative-physician-estimates-for-inflammation-reversible-damage-irreversible-and-distress-in-patients-with-rheumatoid-arthritis-osteoarthritis-and-fib/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology